Patient perceptions of cardiovascular risk, lipid management and statins in type 1 diabetes

被引：1
|
作者：
Lan, Nick S. R. [1 ,3 ,7 ]
Hong, Regina S. Y. [1 ,2 ]
Ryan, Christopher [4 ]
Jenkins, Alicia J. [5 ,6 ]
Fegan, P. Gerry [1 ]
机构：
[1] Fiona Stanley Hosp, Dept Endocrinol & Diabet, Murdoch, WA, Australia
[2] Fiona Stanley Hosp, Dept Cardiol, Murdoch, WA, Australia
[3] Univ Western Australia, Med Sch, Crawley, WA, Australia
[4] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[5] Baker IDI Heart & Diabet Inst, Melbourne, Australia
[6] Curtin Univ, Med Sch, Perth, WA, Australia
[7] Fiona Stanley Hosp, Dept Endocrinol & Diabet, 11 Robin Warren Dr, Murdoch, WA 6150, Australia
来源：
PRIMARY CARE DIABETES | 2023年 / 17卷 / 05期
关键词：
Diabetes mellitus type 1; Cardiovascular diseases; Dyslipidaemias; Statins; Risk factors; ADULTS;
D O I：
10.1016/j.pcd.2023.07.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Lipid-lowering reduces cardiovascular risk in type 1 diabetes (T1D), but dyslipidaemia remains under-recognised and under-treated. Through patient surveys, barriers to lipid management in T1D were identified, including lack of awareness of cardiovascular risk and cholesterol levels, preference for managing glycaemia over lipids, preference for lifestyle modification over pharmacotherapy, and statin side-effect concerns.
引用
收藏
页码：526 / 528
页数：3
相关论文
共 50 条
  • [1] Statins and cardiovascular risk in type 1 diabetes
    Marcovecchio, Loredana
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 14 - 15
  • [2] Lipid management for cardiovascular risk reduction in type 1 diabetes
    Tell, Shoshana
    Nadeau, Kristen J.
    Eckel, Robert H.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2020, 27 (04) : 207 - 214
  • [3] Lipid management to reduce cardiovascular risk in type 2 diabetes
    Brandts, Julia
    DIABETOLOGIE, 2023, 19 (08): : 877 - 884
  • [4] Cardiovascular Risk Management in Type 1 Diabetes
    Teoh, I. H.
    Elisaus, P.
    Schofield, J. D.
    CURRENT DIABETES REPORTS, 2021, 21 (09)
  • [5] Cardiovascular Risk Management in Type 1 Diabetes
    I. H. Teoh
    P. Elisaus
    J. D. Schofield
    Current Diabetes Reports, 2021, 21
  • [6] Beyond Statins: Lipid Management to Reduce Cardiovascular Risk
    Schuck, Robert N.
    Mendys, Philip M.
    Simpson, Ross J., Jr.
    PHARMACOTHERAPY, 2013, 33 (07): : 754 - 764
  • [7] Lipid management with statins in type 2 diabetes mellitus
    Irons, BK
    Kroon, LA
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (10) : 1714 - 1719
  • [8] Improving Lipid Management in Pediatric Type 1 Diabetes (T1D) for Cardiovascular Risk Reduction
    Tell, Shoshana
    Spiegel, Gail
    Thomas, Sarah
    Rottler, Anne
    Gottlieb, David
    Alonso, G. Todd
    HORMONE RESEARCH IN PAEDIATRICS, 2021, 94 (SUPPL 2): : 110 - 110
  • [9] Cardiovascular Disease in Type 1 Diabetes Mellitus: Epidemiology and Management of Cardiovascular Risk
    Colom, Cristina
    Rull, Anna
    Sanchez-Quesada, Jose Luis
    Perez, Antonio
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (08)
  • [10] STATINS AND RISK OF DIABETES Risk of diabetes with statins must be monitored in each patient
    Bifulco, Maurizio
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 347
12345